Tysabri Adds Liver Injury Watch

In an FDA reported letter Biogen and Elan issued concerns about the development of  significant liver damage as a result of  beginning Tysabri therapy.


This entry was posted in news. Bookmark the permalink. Post a comment or leave a trackback: Trackback URL.

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>